Drug Overdose

7

Review clinical trials related to Drug Overdose. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

The ENHANCE Project Toolkit

This study will examine the feasibility, appropriateness, and acceptability of a bundle of smartphone-based tools for lowering overdose risk. 40 participants will be enrolled and can expect to be on study for up to 9 months.

Participants needed: 40
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of Wisconsin, MadisonUpdated: Jun 16, 2026Locations: 1
Eligibility criteria

Be at least 18 years old [+12]

Are under the age of 18 [+4]

Status: Not yet recruiting

Behavioral Safety and Fentanyl Education: BSAFE

BSAFE is a randomized trial of a repeated-dose brief intervention to reduce overdose and risk behaviors among people who use stimulants who may have unintentional fentanyl use (UFU). It includes an established overdose education curriculum within an Informational-Motivation-Behavior (IMB) model. This study will test the efficacy of BSAFE vs attention-control.

Participants needed: 160
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: San Francisco Department of Public HealthUpdated: Jun 9, 2026Locations: 1
Eligibility criteria

Aged 18 years or older, [+4]

Reports past 30-day intentional use of any opioid or ongoing use of an opioid an... [+3]

Status: Recruiting

A Setting Focus Overdose Prevention Intervention

A pilot injection-setting targeted peer-driven intervention to reduce HIV and hepatitis C virus transmission and overdose risk behaviors among people who inject drugs (PWID).

Participants needed: 285
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Johns Hopkins Bloomberg School of Public HealthUpdated: May 22, 2026Locations: 1
Eligibility criteria

Current drug user (opioid use in the prior two weeks)

Any mental or physical health impairment that impedes ability to participate

Status: Not yet recruiting

Justice Community Overdose Innovation Network II TCU Hub

The current study proposes to use a Hybrid Type 3 implementation research strategy to: 1) Significantly enhance our understanding of public health outcomes \[e.g., overdose incidents and substance-use (SU)-related Emergency Medical Service (EMS) contacts\] and public safety outcomes (e.g., drug-related arrests) associated with Deflection and Pre-Arrest Diversion initiatives (DPAD, hereafter referred to as Deflection); and 2) Create a lasting contribution to the fields of research focused on SU and the criminal legal system (CLS) by advancing knowledge of effective implementation strategies involving the critical role of community engagement in Deflection. The highly experienced team of Multiple PIs, senior-level collaborators from both Deflection and Community Behavioral Health (CBH), state-level evaluation partners, a national stakeholder advisory group, and CLS and behavioral health partners within each community have teamed up to carry out the proposed project. The study approach uses a hybrid implementation-effectiveness design to examine strategies to improve opioid and stimulant relevant outcomes, and specifically proposes to test the implementation-effectiveness of 2 strategy bundles to promote Deflection models through a CORE community engagement bundle (designed to facilitate community stakeholder engagement) and ENHANCED community engagement bundle (CORE plus a component to systematically involve community advocates) on improving implementation as well as public safety and health outcomes. The proposed randomized control trial includes a total of 20 geographically distinct clinical research performance sites (i.e., 20 communities spanning 5 states; New Mexico, Illinois, Wisconsin, Colorado, and Pennsylvania), with 3-5 communities per state and the inclusion of key CLS and CBH stakeholders within each site. The large scope of the project will maximize potential generalizability of study results and sustainability of implementation strategies.

Participants needed: 1,620
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Texas Christian UniversityUpdated: Apr 14, 2026Locations: 1
Eligibility criteria

Making referrals (e.g., law enforcement, first responders, community agencies) &... [+3]

Not affiliated with a participating Deflection agency; [+31]

Status: Recruiting

Social Network Overdose Prevention and Education Intervention

The purpose of this study is to test a social intervention focused on overdose prevention and care. In the investigators prior work, the investigators have shown that people who use opioids (PWUO) can be effective peer educators (PEs).

Participants needed: 600
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Johns Hopkins Bloomberg School of Public HealthUpdated: Mar 4, 2026Locations: 1
Eligibility criteria

self-reported illicit opioid use at least 2 times in the past two weeks; [+4]

Status: Recruiting

Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning

This study looks at patients admitted to intensive care for drug poisoning involving metformin, a common diabetes medication. Researchers will compare two groups: patients who overdosed on metformin alone and those who took both metformin and dapagliflozin, another diabetes drug. The goal is to find clinical or laboratory signs that could help doctors quickly recognize a dapagliflozin overdose in this context, which could improve treatment and patient outcomes.

Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Centre Hospitalier de Saint-DenisUpdated: Sep 25, 2025Locations: 1
Eligibility criteria

Adults aged 18 years or older [+3]

Patients under 18 years of age [+2]

Status: Recruiting

CytOSorb TreatMent Of Critically Ill PatientS Registry

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

Participants needed: 3,000
Trial details
Biological sex: AllType: ObservationalSponsor: CytoSorbents, IncUpdated: Sep 11, 2025Locations: 28Duration: 3 Months
Eligibility criteria

Planned OR actual CytoSorb® 300 mL device utilization [+1]

Use of the CytoSorb® 300 mL device for antithrombotic removal only [+2]